# Reducing Supply Risk in Rare Disease Trials: Why Every Dose Matters  ![](https://www.endpointclinical.com/wp-content/uploads/2026/11/Site-Blog-Images-1024x512.png)In rare disease clinical trials, every patient matters. Every dose matters. And every supply decision carries significant weight. Small patient populations, limited investigational product, and global distribution requirements make clinical supply management especially complex. Sponsors must position scarce drug where it can be used, while avoiding preventable expiry and treatment interruptions. That requires more than simply maintaining inventory buffers at every site. ###### **Limited Supply Changes the Planning Equation** Rare disease therapies may be produced in small batches with long manufacturing lead times and limited opportunities for replenishment. Holding excess stock at every site can tie up valuable supply and increase the risk of waste; holding too little can leave a site unprepared when an eligible patient enrolls. The priority is to allocate available inventory based on actual study requirements, with visibility into what is on hand, where it is located, and whether it can be used in time. ###### **Global Dispersion Adds Operational Complexity** Eligible patients may be spread across many regions. A trial involving 50 patients, for example, may require sites across 15 countries. Each country can introduce distinct import requirements, depot arrangements, and shipping lead times. This makes country- and depot-level planning essential. Inventory that is available somewhere in the study is not necessarily accessible to the site that needs it. A transfer may be constrained by country eligibility, transit time, or the remaining usable shelf life of the product. ###### **Expiry-Aware Resupply: Planning for Usable Supply** Unpredictable enrollment and changing treatment schedules can make it difficult to anticipate when and where supply will be needed. Resupply decisions must consider whether available inventory will remain within expiry through shipment, receipt, and the planned dispensing or administration date, as applicable. **Consider an illustrative scenario:** A site in Country A expects to dispense treatment in three weeks. A nearby depot has units available, but their expiry dates leave insufficient time for the shipment and planned use. Another depot has longer-dated stock, yet that stock may not be eligible for import into Country A or may require a longer shipping window. The appropriate resupply decision depends on all four factors: depot availability, country eligibility, shipment lead time, and usable shelf life. Evaluating those constraints together helps teams avoid selecting inventory that looks available on paper but cannot support the patient’s treatment schedule. It can also help identify opportunities to use eligible, earlier-expiring stock before it becomes waste. ###### **Supporting Precise Supply Decisions With RTSM** At **Endpoint Clinical**, we recognize that rare disease studies need supply processes that respond to changing operational conditions while preserving control. Through depot- and country-level supply logic and visibility into each unit’s applicable expiry date, Endpoint supports inventory allocation and resupply decisions based on configured study requirements. These capabilities can help teams assess available stock, apply study-specific rules, and support appropriate replenishment as enrollment and treatment needs evolve. RTSM is one part of the broader supply process: import rules, logistics execution, and sponsor oversight remain critical. Bringing relevant inventory and expiry information into resupply decisions helps clinical teams manage finite supply with greater precision. ###### **Protecting Every Dose, Supporting Every Patient** In rare disease research, supply decisions have an outsized impact. Better alignment of inventory location, country requirements, shipping timelines, and expiry can help reduce avoidable waste and support continuity of investigational treatment. Because in rare disease trials, protecting supply is ultimately about protecting the opportunity to treat every patient. ###### **Watch the Video: Reducing Supply Risk in Rare Disease Trials** **Jeff Rubesin, VP of Strategy & Product at Endpoint Clinical,** discusses the unique supply challenges of rare disease trials and how thoughtful RTSM strategies can help maintain investigational treatment availability for enrolled patients. Watch the video to learn more: